Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{166300,
        author = {Bhingole Yogita Pralhadro and Dr. Vivek B. Panchabhai and Mr. Naragude A. D.  and Patil Poonam Madhavrao},
        title = {Design, Synthesis, and Molecular Docking Studies of Sulfadiazine Schiff Base Derivatives as Potential Anti-mycobacterial Agents},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {2},
        pages = {1761-1765},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=166300},
        abstract = {Tuberculosis (TB) remains a global health challenge, necessitating the development of alternative therapeutic agents, particularly against multidrug-resistant strains. In this study, we designed and synthesized a series of sulfadiazine Schiff base derivatives and evaluated their potential as anti-mycobacterial agents. Molecular docking studies were conducted to assess the binding affinity of these compounds with the enoyl-ACP reductase enzyme, a key target in TB treatment. The synthesized compounds demonstrated promising docking scores, with molecules S3, S5, and S8 showing the highest binding affinities. Additionally, the compounds exhibited significant antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as fungi. These findings suggest that sulfadiazine Schiff base derivatives hold potential as lead compounds for the development of novel antimycobacterial drugs. Further experimental validation and optimization are warranted to explore their therapeutic efficacy against TB and related diseases.},
        keywords = {Tuberculosis, antimycobacterial, enoyl-ACP reductase enzyme.},
        month = {July},
        }